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ELECTRON MICROSCOPIST’S VIEW OF THE ALzHEIMER’S PLAQUE
Krikor Dikranian  
Department of Anatomy and Neurobiology, Washington University in Saint Louis, Saint Louis, MO, USA
Alzheimer’s disease (AD) is characterized by extracellular aggregation and deposition of Amyloid-beta peptide in the form of 
diffuse and fibrillar plaques. More than 50 years ago electron microscopic studies in humans have characterized the structure 
of the amyloid plaque and neurofibrillary tangles. More recently animal models of AD-type amyloidosis have provided excellent 
opportunities to study plaque structure during the development and expression of AD-type pathology. Ultrastructural data from 
a variety of transgenic mice overexpressing mutant amyloid precursor proteins, mutant presenilins, with or without human ApoE 
knock-in isoforms, are highly comparable to classical electron microscopic findings in AD. This review is an attempt to evaluate, 
from an electron microscopist’s point of view, the structural identity of AD type pathology, and the mature amyloid plaque in 
particular. Biomed Rev 2012; 23: 9-17.
Key words: amyloid plaque, fibrils, neurites, apoptosis, autophagic vacuoles
PROLOGUE
In November 1901, Dr Alois Alzheimer admitted Auguste 
D., a 51 year old patient, to the Frankfurt hospital because of 
progressive memory loss, delusions and hallucinations. On the 
3rd of November 1906, Dr Alzheimer delivered a lecture at 
the meeting of the Psychiatrists of South West Germany where 
he presented the clinicopathological data from his long time 
patient Auguste D. who suffered from “presenile dementia” 
and died at the age of 55. His presentation would not have 
been possible without the development of new and special 
staining techniques by Max Bielschowsky (silver staining) 
and his friend Franz Nissl (Nissl staining) who introduced 
him to brain histopathology. Four years later, in 1910 the 
great psychiatrist and his senior colleague Emil Kraepelin 
proposed the name Alzheimer’s disease (AD). Regretfully, 
as is the case with so many great achievements in science, 
history and art, what was not properly acknowledged at that 
time, was the equally important contribution of another man - a 
young Italian physician, Dr Gaetano Perusini. Together with 
Dr Alzheimer he studied Auguste D.‘s brain. As witnessed by 
many publications, Dr Alzheimer himself expressed his wish to 
entrust the investigation of this “new” disease to Dr Perusini. 
In fact the first 4 cases of Alzheimer’s disease published by 
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Alzheimer’s laboratory were authored by Perusini. In 1998 
an Italian colleague, B. Lucci, described the contribution of 
his country fellow in the article entitled “Тhe contribution of 
Gaetano Perusini to the definition of Alzheimer’s disease” 
published in Italian Journal of Neurological Sciences 19: 
49–52. Recently, the silver stained slides of Auguste D’s brain 
have been rediscovered and their re-examination has confirmed 
that what was described then represents the same diagnostic 
entity that we recognize now. In the same line of thoughts 
it would have been very helpful to understand if her case 
was related to the autosomal dominant form of this disease, 
but regretfully, no family history for Frau Auguste has been 
retrieved to this date.
INTRODUCTION
Alzheimer’s disease is characterized by the formation of 
amyloid plaques, progressive degeneration of neuronal 
populations in the neocortex and limbic system, appearance 
of neurofibrillary tangles and by cognitive impairment that is 
manifested decades after brain tissue pathology has begun. 
More than 50 years ago Robert Terry and Michael Kidd 
presented their very detailed ultramorphological studies 
on the amyloid plaque in postmortem AD brains. They 
described the characteristic neuritic changes and the structure 
of neurofibrillary tangles formed by paired helical filaments 
(PHF) in dystrophic or dying neurons (1-5). AD plaques 
were described of being composed of extracellular deposits 
of amyloid-β (Aβ) and other plaque-associated proteins and 
surrounded by dystrophic neurites and glial cells. A classical 
plaque had a “central fibrillar core”, “axons and dendrites 
filled with an excess of neurofibrils”, and “cell processes filled 
with dense bodies” (4). The earliest sign of plaque formation 
according to Wisniewski and Terry was the appearance of few 
abnormal neurites, followed by “wisps” of deposited amyloid 
(6). In 1989 Yamaguchi et al characterized the structure of the 
“diffuse plaque” (7). In 1992 they described the deposition 
of amyloid in AD related angiopathy (8). Scanning electron 
microscopy has also been applied mainly for the study of 
tangles and PHF (9). Since 1996 few systemic human electron 
microscopic (EM) studies have been published (10,11).
THE ERA OF THE TRANSGENIC MOUSE MODEL OF AD 
The generation of transgenic (tg) mice as models overexpressing 
mutant human amyloid precursor protein (APP) and/or 
presenilin 1 (PS1) and PS2, tg APP/PS1 mice expressing 
in addition the human apolipoprotein E (ApoE) isoforms, 
as well as mutant Tau, has made substantial contributions 
to understanding of the structural changes in the brain 
during the development of the AD-type pathology (12-17). 
Importantly, they have replicated major pathological features 
such as the diffuse and compact amyloid plaque, the massive 
neuritic dystrophy, and glial activation (11, 18-20). No mouse 
model has fully recapitulated the entire neuropathological 
spectrum of AD-like brain lesions, like PHF in dystrophic 
neurons. Nevertheless tg animals have been an invaluable 
tool to study AD (21-24). Since no PHF were observed even 
in the oldest PDAPP mice, many have agreed that other 
approaches such as accelerated aging or increased longevity 
of experimental mice might be needed to recapitulate tangle 
pathology (18). Historically the first animal tg models were 
based on the overexpression of single or multiple mutant 
molecules associated with familial AD (FAD) (16). Masliah et 
al made a detailed EM comparison of the neurodegenerative 
pathology found in AD and the PDAPP tg mouse line (11, 16). 
Overproduction of a mutant human APP in mice produced 
amyloid fibril deposition, diffuse and mature amyloid plaque 
formation at 8 months of age. Axonal dystrophy, microglial 
and astroglial involvement have been reported by this and 
other groups (11, 18, 25). In many human and animal studies 
the relationship between amyloid deposition/turnover and 
microglia has been extensively discussed (2, 11, 19, 26-32). 
To date however, it remains poorly understood. Various reports 
show that microglia cells may be the driving force in depositing 
or clearing fibrillar amyloid (31-34). Others like Grathworth 
et al have shown that the formation and maintenance of the 
amyloid plaque can occur in almost complete absence of 
microglia and that neuritic dystrophy may develop independent 
of microglia (35).
 Kurt et al (2001) provided the first detailed ultrastructural 
study on tg mice co-expressing mutant APP and PS1 (19). They 
showed robust amyloid deposition months earlier than APP tg 
mice. A number of other studies using different APP tg models 
have all reported mature amyloid plaques (36-42). Based on 
these and other studies, overwhelming evidence has been 
accumulated to support the idea that FAD-like mouse models 
produce extensive amyloid plaque, microglial cell activation 
and axonal dystrophy (11, 26, 38). Our ultrastructural studies 
in three (Fig. 1) and seven months old APP/PS1 transgenic 
mice have shown that the structure of the plaque and its 
immediate surroundings also strikingly resemble classical 
finding in humans (1-5). In these tg mice the mature amyloid 
plaque also presented with a dense fibrillar core surrounded 
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by a great number of elaborate microglial cell processes 
forming characteristic invaginations (or bays) where parallel 
amyloid fibrils accumulated (Fig. 1). Importantly, microglial 
processes showed morphological signs of phagocytic activity 
with neuritic debris and/or aggregation of lysosomes. This also 
appeared to be true for microglia that surrounds the plaque 
periphery. Studies have shown that in tg AD-like mouse 
models microglial response around plaques occurs often and 
relatively soon (43-44). 
The ε4 allele of ApoE is known so far to be the only firmly 
established risk factor for the more common sporadic forms of 
AD (39-41). Our extensive ultrastructural examination of the 
mature plaque structure and neuritic pathology in seven month 
old APP/PS1 tg mice each expressing one of the three human 
ApoE isoforms - ApoE2, ApoE3 and ApoE4 (45) have shown 
that all the signature signs of the mature neuritic AD-like plaque 
are also observed at this time point. Structurally, the plaque and 
axonal degeneration morphologies were also similar to that 
of tg APP/PS1 mice with the mouse ApoE (Fig. 1-3; see also 
Sanchez-Varo et al. 2012). Even at 3 months of age APP/PS1 
mice exhibit a number of very dystrophic axonal terminals 
with synaptic figures that seem to have preserved their pre- and 
Figure 1. Low power electron micrograph of a mature amyloid plaque seen in the cortex of APP/PS1 tg animal. The amyloid 
core is represented by a star-shaped epicenter (*), surrounded by many processes (black arrow) of microglial cells. One of these 
processes at the lower right shows autophagic vacuoles (white arrow). The amyloid core is surrounded by corona of dystrophic 
spheroids (**) filled with degenerating mitochondria, autophagic vacuoles and lysosome-like structures.
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Figure 2. Electron micrograph showing higher magnification of two moderately degenerated axons with normal mitochondria 
(*) and autophagic vacuoles (**).
Figure 3. Electron micrograph showing axonal profiles at advanced stage of degeneration. At the center of this micrograph, a 
grossly degenerated terminal with preserved pre- and post- synaptic density and condensed axoplasmic matrix is also observed.
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post synaptic density (Fig. 3); interestingly, the postsynaptic 
dendritic shafts and spines did not show evidence of dystrophy. 
Grossly dilated and dystrophic presynaptic terminals have been 
discussed in aged APP751 (Swedish double mutation) tg mice 
(38), in 4 month old PS1M146L/APP751SL tg mice with human 
ApoE (46). The latter findings were discussed as the initial 
degenerative process underlying functional disturbance prior 
to neuronal loss. We have found that a corona of degenerating 
neuritic processes is represented by profiles at different stages 
of swelling and dystrophy and organelle compaction (Fig. 
1-3). We also observed that in APP/PS1 tg mice and also tg 
APP/PS1 with human ApoE isoform knock-in tg mice (45) 
morphological changes in myelinated axons distant from the 
plaque and the swollen and dystrophic profiles within the 
plaque are strikingly similar. We have been also consistently 
encountered transitions from myelinated to unmyelinated 
segments along a single axon and these segments contained 
similar dystrophic changes. Based on such observations we can 
speculate with high degree of confidence that the vast majority 
of “dystrophic neuritic profiles” are indeed demyelinated 
segments of axons. To date almost all ultrastructural studies 
agree with this concept (25, 37, 46). Electron microscopic 
studies in postmortem AD also support the predominant axonal 
origin of the plaque’s dystrophic neurites (12, 47-49). Many 
years ago, in their classical ultrastructural studies, Tery and 
Wisniewski (1-2) have suggested that the earliest precursors of 
the senile plaque is the abnormally swollen and degenerating 
neurite filled with numerous mitochondria, lamellar and dense 
bodies. They even proposed that plaques develop from small 
clusters of these dystrophic neurites. In good agreement with 
APP-immunoreactive spheroids in an early onset AD patients, 
motor deficits have been reported (47, 50-51). Likewise in 10 
and 14 months old APP/PS1 models, in mice transgenic for 
human four-repeat tau, or human ApoE4, evidence for motor 
deficits caused by substantial disturbance of axonal transport 
and spinal cord axonal degeneration has been reported (52). It 
has been suggested that axonal swellings such as these found 
in and around the plaque, precede and participate in plaque 
formation, probably due to focally increased Aβ secretion 
or lysis of Aβ rich swellings (53). Plaques with identical 
morphology have been observed by us and by others (19, 45) 
in the white matter as well. Since white matter is devoid of 
neuronal cell bodies, dendritic processes and axonal terminals, 
it has been speculated that amyloid deposition is likely to 
be extraneuronal (19). The evolution of dystrophic axonal 
changes included in addition diverse axoskeletal abnormalities. 
Similar observations have been reported in APP tg mice, APP/
PS1 tg mice, tg mice with human four-repeat tau proteins 
and in mice expressing mutant human tau (11, 19, 38, 46, 
54, 55-57). Axonal swelling, the cytoskeletal pathology, 
accumulation of dystrophic organelles, such as mitochondria 
and autophagic vacuoles, while indicative of progressive 
axonal degeneration, may also indicate disturbed organelle 
(anterograde/retrograde) transport (54, 57). Interestingly we 
have often observed instances of only normal mitochondrial 
accumulation in dilated segments along the neuirite. Changes 
in the axoplasmic cytoskeleton in association with organelle 
compaction have been consistently observed in experimental 
traumatic brain injury and these features have been classically 
interpreted as axonal transport impairment (58-59). Impaired 
axonal transport appears to be a major pathological alteration 
in later stages of the AD progression and the axonal pathology 
described by us and others recapitulates the cardinal features 
of axonal impairment and possible chronic deficits not only 
in motor performance.
Currently it is still unclear whether dementia and 
neurodegeneration are equal to loss of neurons, loss of 
functional synapses or disturbances of synaptic transmission. 
Although not directly observed within the plaque, neuronal cell 
death of non-apoptotic and/or apoptotic origin is an important 
part of the pathogenesis of the disease and reflects the cause/
consequence paradigm of AD. Mitochondrial dysfunction 
and oxidative stress in degenerating neurites as causative 
factors for the progressive cell death occurring in tg animals 
has also been discussed (60). In general, however cell death 
has emerged as a controversial topic. The exact mechanism of 
cell death in neurons that develop tangles in AD is not known. 
In our single time-point studies there was no ultrastructural 
indication of autophagic or apoptotic cell death although many 
axonal processes exhibited pathology consistent with the 
process of autophagy. Our data are similar to data from APP/
PS1 tg mice where the lysosomal pathology was prevailing 
in degenerating neurons of older animals (19, 61). It is also 
difficult to argue that axonal pathology and neuronal cell death 
are directly related since we have found much less neuronal cell 
body degeneration compared to the massive axonal dystrophy 
throughout the brain. Nonetheless, non-apoptotic type of cell 
death can be substantial given the protracted nature of the 
disease observed in these animals. Neuronal apoptosis on the 
other hand has been implicated in aging APP/PS mice (60, 
62) based on a number of activated caspase 3 immunoreactive 
cells (marker of apoptotic cell death) and ultrastructural 
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morphology. However the involvement of this cell death type 
in tg animals remains rather uncertain (63). The involvement 
of apoptotic cell death is also unclear in human AD cases (64). 
Implicating the potential role of autophagic neuronal cell death, 
Yang et al have presented evidence for a cross talk between 
apoptosis and autophagy by showing robust activated caspase 3 
staining in autophagic vacuoles in dystrophic neurites of APP/
PS1 tg mice (62). In AD brains certain hippocampal neurons 
have shown features of granulovacuolar degeneration with the 
expression of activated caspase 3 (65). Although such findings 
reinforce the idea of possible link between apoptotic and 
autophagic neuronal cell death in some experimental models, 
and also in AD, further studies are needed to clarify the exact 
nature of cell degeneration. 
CONCLUDING REMARKS
After reviewing published EM data from AD, tg APP/PS1 
mice with mutant tau, our own data from single tg APP mice, 
double tg APP/PS1 mice, and tg APP/PS1 mice expressing 
human ApoE isoforms, we conclude that at ultramicroscopic 
level they all share the cardinal features of the classic senile 
plaque. Clinically, despite variable and divergent genetic 
causes, the outcome in all AD patients is similar as they 
present with unique postmortem pathology (66). Therefore 
these tg animals, in addition to being extremely useful for 
the study of the pathogenesis of AD, they also offer models 
for the development of treatment strategies. Studies of FAD 
have contributed to the identification of important molecular 
processes. Studies on sporadic and late-onset AD cases have 
shown the relevance of ApoE variants and the population 
of patients at risk. They have also prompted the search for 
additional genetic candidates that may produce more complete 
transgenic animal models that harbor different combination 
of AD - related human genes. There are, of course many 
unanswered questions. It is still debated whether dominantly 
inherited AD and “sporadic” forms express identical biomarker 
signatures. Sporadic AD is currently conceptualized as a 
complex, nonlinear, dynamic, and chronically progressive 
disease and it will be interesting to know if EM can be of any 
help in charting possible morphological differences. Animal 
models will help in unraveling the precise mechanism of 
amyloid secretion, cell and axon degeneration and of synapse 
dystrophy and elimination. While this search is on, the EM 
evaluation of the morphological changes will likely still remain 
a “golden standard” in the complex approach in resolving the 
various aspects of this dehumanizing disease.
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